09/23/2024 |
The commercial law firm Oppenhoff is strengthening its healthcare and M&A practice with Franziska Katterbach as a new partner at its Frankfurt office. Katterbach will join Oppenhoff on October 1, 2024 from Khiron Life Sciences, a medical cannabis company, reports Legal Tribune Online.
She was previously Managing Director for Khiron’s European business and also worked for Canopy Growth, also in the cannabis sector. Katterbach previously worked as a lawyer at Dentons, where she gained experience in the life sciences sector. Her move to Oppenhoff marks the third addition at partner level in Frankfurt this year, after Dr. Regina Engelstädter and Dr. Barnim von den Steinen have already joined the firm.
Expansion in healthcare: Franziska Katterbach new partner at Oppenhoff
Oppenhoff has appointed Franziska Katterbach as a new partner in its Healthcare / M&A department at the Frankfurt office as of 1 October 2024. Previously, she built up the European business as Managing Director at Khiron Life Sciences, a manufacturer and distributor of medical cannabis and operator of clinics.
Franziska Katterbach has many years of experience in the healthcare sector and in the cannabis industry in particular. Following her law studies, she began her career at Dentons, where she provided legal advice on international transactions, particularly in the life sciences sector. In 2018, Franziska Katterbach joined Canopy Growth Corporation as Director of Legal, Europe, before joining Khiron Life Sciences in 2019. At both companies, she navigated the European business through the highly regulated narcotics sector.
Myriam Baars-Schilling, the law firm’s chairwoman, stated: “We are delighted to have Franziska Katterbach strengthen our healthcare business with her high-calibre expertise. Her professional competence and in-depth industry knowledge are extremely valuable for our customised client work in this important future-oriented sector.”
Franziska Katterbach stated: “I am delighted to be joining the Oppenhoff team and to be able to contribute my international expertise to the client work with important players in the healthcare and pharmaceutical industry.”
Oppenhoff’s Healthcare sector group advises leading international pharmaceutical manufacturers, medical device manufacturers, biotech companies, hospitals, nursing homes, health insurance companies and service providers on day-to-day business, M&A transactions, regulatory issues, competition law and the German Medical Products Advertising Act and on securing industrial property rights. Together with clients, new solutions and business models are constantly being developed, for example for the digitisation of medical products, the cultivation of medical cannabis in Germany or development cooperations with start-ups.
Most recently, Oppenhoff was able to recruit Dr. Regina Engelstädter and Dr. Barnim von den Steinen for its corporate practice in Frankfurt.
